Related references
Note: Only part of the references are listed.PSMA-Targeting Imaging and Theranostic Agents-Current Status and Future Perspective
Sashi Debnath et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Theranostic Small-Molecule Prodrug Conjugates for Targeted Delivery and Controlled Release of Toll-like Receptor 7 Agonists
Sashi Debnath et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Clinical and Biological Features of Neuroendocrine Prostate Cancer
Yasutaka Yamada et al.
CURRENT ONCOLOGY REPORTS (2021)
Validation of SV2A-Targeted PET Imaging for Noninvasive Assessment of Neuroendocrine Differentiation in Prostate Cancer
Bing Guan et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Knocking down claudin receptors leads to a decrease in prostate cancer cell migration, cell growth, cell viability and clonogenic cell survival
Qiang Liu et al.
MOLECULAR BIOMEDICINE (2021)
Epigenetic Regulation of Gfi1 in Endocrine-Related Cancers: A Role Regulating Tumor Growth
Nadia Ashour et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer
Laura Cato et al.
CANCER CELL (2019)
Database-augmented Mass Spectrometry Analysis of Exosomes Identifies Claudin 3 as a Putative Prostate Cancer Biomarker
Thomas Stefan Worst et al.
MOLECULAR & CELLULAR PROTEOMICS (2017)
Cancer Statistics, 2016
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Development of Castration Resistant Prostate Cancer can be Predicted by a DNA Hypermethylation Profile
Javier C. Angulo et al.
JOURNAL OF UROLOGY (2016)
Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer
Kristine M. Wadosky et al.
ONCOTARGET (2016)
Enzalutamide in Castration-resistant Prostate Cancer Patients Progressing After Docetaxel and Abiraterone
Andres Jan Schrader et al.
EUROPEAN UROLOGY (2014)
Androgen-Dependent Sertoli Cell Tight Junction Remodeling Is Mediated by Multiple Tight Junction Components
Papia Chakraborty et al.
MOLECULAR ENDOCRINOLOGY (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy REPLY
Tomasz M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
A DNA Hypermethylation Profile Reveals New Potential Biomarkers for Prostate Cancer Diagnosis and Prognosis
Nadia Ashour et al.
PROSTATE (2014)
CLDN3 inhibits cancer aggressiveness via Wnt-EMT signaling and is a potential prognostic biomarker for hepatocellular carcinoma
Lei Jiang et al.
ONCOTARGET (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
T. M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Renal tubular Sirt1 attenuates diabetic albuminuria by epigenetically suppressing Claudin-1 overexpression in podocytes
Kazuhiro Hasegawa et al.
NATURE MEDICINE (2013)
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches
T. Karantanos et al.
ONCOGENE (2013)
Regulation of the Epithelial-Mesenchymal Transition by Claudin-3 and Claudin-4
Xinjian Lin et al.
PLOS ONE (2013)
Methylation of the Claudin 1 Promoter Is Associated with Loss of Expression in Estrogen Receptor Positive Breast Cancer
Francescopaolo Di Cello et al.
PLOS ONE (2013)
Molecular Pathogenesis and Progression of Prostate Cancer
Randy Schrecengost et al.
SEMINARS IN ONCOLOGY (2013)
Androgen receptor (AR) aberrations in castration-resistant prostate cancer
Kati K. Waltering et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2012)
Tight Junction Proteins Claudin-3 and Claudin-4 Control Tumor Growth and Metastases
Xiying Shang et al.
NEOPLASIA (2012)
Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy
Changmeng Cai et al.
ENDOCRINE-RELATED CANCER (2011)
Alternatively spliced androgen receptor variants
Scott M. Dehm et al.
ENDOCRINE-RELATED CANCER (2011)
Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer
Qianben Wang et al.
CELL (2009)
Epithelial-Mesenchymal Transitions in Development and Disease
Jean Paul Thiery et al.
CELL (2009)
Claudin-3 gene silencing with siRNA suppresses ovarian tumor growth and metastasis
Yu-Hung Huang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Claudins 1, 3, and 4 protein expression in ER negative breast cancer correlates with markers of the basal phenotype
Anne A. Blanchard et al.
VIRCHOWS ARCHIV (2009)
Regulation of the CLDN3 gene in ovarian cancer cells
Hiroshi Honda et al.
CANCER BIOLOGY & THERAPY (2007)
EGF prevents the neuroendocrine differentiation of LNCaP cells induced by serum deprivation:: The modulator role of PI3K/Akt
Rosa M. Martin-Orozco et al.
NEOPLASIA (2007)
Alien interacts with the human androgen receptor and inhibits prostate cancer cell growth
Udo Moehren et al.
MOLECULAR ENDOCRINOLOGY (2007)
DNA-methylation-dependent alterations of claudin-4 expression in human bladder carcinoma
Stephanie Boireau et al.
CARCINOGENESIS (2007)
Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer
Hui Gao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
The claudin gene family: expression in normal and neoplastic tissues
Kyle J. Hewitt et al.
BMC CANCER (2006)
Genome-wide analysis of mammalian promoter architecture and evolution
Piero Carninci et al.
NATURE GENETICS (2006)
Direct interaction of two polarity complexes implicated in epithelial tight junction assembly
TW Hurd et al.
NATURE CELL BIOLOGY (2003)
Share Paper
